These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

632 related items for PubMed ID: 33357209

  • 1. MicroRNA Regulation of Androgen Receptor in Castration-Resistant Prostate Cancer: Premises, Promises, and Potentials.
    Ebrahimi S, Hashemy SI, Sahebkar A, Aghaee Bakhtiari SH.
    Curr Mol Pharmacol; 2021 Oct 25; 14(4):559-569. PubMed ID: 33357209
    [Abstract] [Full Text] [Related]

  • 2. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
    Shafi AA, Yen AE, Weigel NL.
    Pharmacol Ther; 2013 Dec 25; 140(3):223-38. PubMed ID: 23859952
    [Abstract] [Full Text] [Related]

  • 3. Targeting the androgen receptor signaling pathway in advanced prostate cancer.
    Chung C, Abboud K.
    Am J Health Syst Pharm; 2022 Jul 22; 79(15):1224-1235. PubMed ID: 35390118
    [Abstract] [Full Text] [Related]

  • 4. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.
    Karantanos T, Evans CP, Tombal B, Thompson TC, Montironi R, Isaacs WB.
    Eur Urol; 2015 Mar 22; 67(3):470-9. PubMed ID: 25306226
    [Abstract] [Full Text] [Related]

  • 5. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.
    Lee CH, Ku JY, Ha JM, Bae SS, Lee JZ, Kim CS, Ha HK.
    Prostate; 2017 Jan 22; 77(1):60-71. PubMed ID: 27550197
    [Abstract] [Full Text] [Related]

  • 6. Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer.
    Wadosky KM, Koochekpour S.
    Oncotarget; 2016 Sep 27; 7(39):64447-64470. PubMed ID: 27487144
    [Abstract] [Full Text] [Related]

  • 7. Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis.
    Yuan X, Cai C, Chen S, Chen S, Yu Z, Balk SP.
    Oncogene; 2014 May 29; 33(22):2815-25. PubMed ID: 23752196
    [Abstract] [Full Text] [Related]

  • 8. siRNA-based approaches for castration-resistant prostate cancer therapy targeting the androgen receptor signaling pathway.
    Yu Y, Papukashvili D, Ren R, Rcheulishvili N, Feng S, Bai W, Zhang H, Xi Y, Lu X, Xing N.
    Future Oncol; 2023 Sep 29; 19(30):2055-2073. PubMed ID: 37823367
    [Abstract] [Full Text] [Related]

  • 9. Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles.
    Hoang DT, Iczkowski KA, Kilari D, See W, Nevalainen MT.
    Oncotarget; 2017 Jan 10; 8(2):3724-3745. PubMed ID: 27741508
    [Abstract] [Full Text] [Related]

  • 10. Downregulation of Dipeptidyl Peptidase 4 Accelerates Progression to Castration-Resistant Prostate Cancer.
    Russo JW, Gao C, Bhasin SS, Voznesensky OS, Calagua C, Arai S, Nelson PS, Montgomery B, Mostaghel EA, Corey E, Taplin ME, Ye H, Bhasin M, Balk SP.
    Cancer Res; 2018 Nov 15; 78(22):6354-6362. PubMed ID: 30242112
    [Abstract] [Full Text] [Related]

  • 11. Androgen receptor: what we know and what we expect in castration-resistant prostate cancer.
    Cai Z, Chen W, Zhang J, Li H.
    Int Urol Nephrol; 2018 Oct 15; 50(10):1753-1764. PubMed ID: 30128923
    [Abstract] [Full Text] [Related]

  • 12. Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence.
    Coutinho I, Day TK, Tilley WD, Selth LA.
    Endocr Relat Cancer; 2016 Dec 15; 23(12):T179-T197. PubMed ID: 27799360
    [Abstract] [Full Text] [Related]

  • 13. Adaptive responses of androgen receptor signaling in castration-resistant prostate cancer.
    Perner S, Cronauer MV, Schrader AJ, Klocker H, Culig Z, Baniahmad A.
    Oncotarget; 2015 Nov 03; 6(34):35542-55. PubMed ID: 26325261
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Platelet-Synthesized Testosterone in Men with Prostate Cancer Induces Androgen Receptor Signaling.
    Zaslavsky AB, Gloeckner-Kalousek A, Adams M, Putluri N, Venghatakrishnan H, Li H, Morgan TM, Feng FY, Tewari M, Sreekumar A, Palapattu GS.
    Neoplasia; 2015 Jun 03; 17(6):490-6. PubMed ID: 26152357
    [Abstract] [Full Text] [Related]

  • 18. ASC-J9(®) suppresses castration resistant prostate cancer progression via degrading the enzalutamide-induced androgen receptor mutant AR-F876L.
    Wang R, Lin W, Lin C, Li L, Sun Y, Chang C.
    Cancer Lett; 2016 Aug 28; 379(1):154-60. PubMed ID: 27233475
    [Abstract] [Full Text] [Related]

  • 19. CaV1.3 enhanced store operated calcium promotes resistance to androgen deprivation in prostate cancer.
    O'Reilly D, Downing T, Kouba S, Potier-Cartereau M, McKenna DJ, Vandier C, Buchanan PJ.
    Cell Calcium; 2022 May 28; 103():102554. PubMed ID: 35193095
    [Abstract] [Full Text] [Related]

  • 20. Exploring anti-androgen therapies in hormone dependent prostate cancer and new therapeutic routes for castration resistant prostate cancer.
    Harris AE, Metzler VM, Lothion-Roy J, Varun D, Woodcock CL, Haigh DB, Endeley C, Haque M, Toss MS, Alsaleem M, Persson JL, Gudas LJ, Rakha E, Robinson BD, Khani F, Martin LM, Moyer JE, Brownlie J, Madhusudan S, Allegrucci C, James VH, Rutland CS, Fray RG, Ntekim A, de Brot S, Mongan NP, Jeyapalan JN.
    Front Endocrinol (Lausanne); 2022 May 28; 13():1006101. PubMed ID: 36263323
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.